Cloudbreak Pharma, based in Irvine, California, is a clinical-stage pharmaceutical company that specializes in the research and development (R&D) of drugs for ocular diseases. Founded in September 2015, the company operates in the healthcare sector, specifically in the ophthalmic drug market. The team at Cloudbreak Pharma is diverse and has extensive experience in ocular drug R&D, which is the process of discovering, testing, and producing new drugs to treat eye diseases.

The company's business model revolves around the development of innovative treatments for various ocular diseases. These include pterygium (a growth on the eye's surface), pinguecula (a yellowish bump on the eye), meibomian gland dysfunction (a common type of dry eye disease), glaucoma filtration surgery, adjunct therapy for glaucoma filtration surgery, age-related macular degeneration (a common eye condition among people over 50), and diabetic retinopathy (a diabetes complication that affects eyes).

Cloudbreak Pharma's products are at different stages of pre-clinical and clinical development. The company generates revenue through the successful development, approval, and subsequent sale of these drugs. Its mission is to improve people's vision and quality of life through medicine, with a particular focus on creating the first therapeutic treatment for pterygia.

Keywords: Ophthalmic Drugs, Clinical-Stage Pharmaceutical Company, Ocular Diseases, Research and Development, Pterygium, Pinguecula, Meibomian Gland Dysfunction, Glaucoma Filtration Surgery, Age-Related Macular Degeneration, Diabetic Retinopathy.